ABBV catalysts
Catalysts and events linked to ABBV, newest first.
Do these developments change your position?
Review ABBV alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-09-06Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologicsABBV REGN
- 2026-09-06Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics DemandABBV LLY REGN
- 2026-09-06Atopic Dermatitis Biopharma Market Projected to Reach $33.4B by 2035 at 7.7% CAGRABBV LLY REGN
- 2026-09-06Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGRABBV LLY REGN
- 2026-08-30Eli Lilly Posts 45% Top-Line Growth but Faces Two-Thirds GLP-1 Revenue ConcentrationABBV LLY
- 2026-08-30Eli Lilly GLP-1 Portfolio Generates Two-Thirds of Total Revenue Amid 45% Top-Line GrowthABBV LLY
- 2026-08-30Eli Lilly GLP-1 Revenue Hits Nearly Two-Thirds of Sales Amid 45% Top-Line GrowthABBV LLY
- 2026-08-30Eli Lilly GLP-1 Portfolio Delivers 45% Growth as Concentration Nears Two-Thirds RevenueABBV LLY
- 2026-08-07Nxera Pharma Revenue Jumps on R&D Milestones with AbbVie and LillyABBV LLY
- 2026-06-29Study Shows 16% of Patients Return to Humira After Biosimilar SwitchABBV
- 2026-06-29Study Shows 16% of Patients Return to Humira After Biosimilar SwitchABBV
- 2026-05-26Viking, AbbVie poised for obesity drug market growth.ABBV VKTX
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.